PROCEPT BioRobotics (NASDAQ:PRCT) Reaches New 1-Year Low After Earnings Miss

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) reached a new 52-week low during mid-day trading on Thursday following a dissappointing earnings announcement. The company traded as low as $19.35 and last traded at $20.9420, with a volume of 1508954 shares trading hands. The stock had previously closed at $27.84.

The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.21). The firm had revenue of $76.38 million for the quarter, compared to analyst estimates of $93.70 million. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.PROCEPT BioRobotics’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.35) earnings per share.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Management issued FY‑2026 revenue guidance of $390M–$410M, modestly above consensus, suggesting longer‑term growth expectations remain intact. PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
• Positive Sentiment: The company hosted a 2026 Investor Day to lay out its multi‑year financial outlook and strategic plan, which could support confidence if management delivers execution and cadence at upcoming milestones. PROCEPT BioRobotics Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth
• Neutral Sentiment: Independent bullish write‑ups and analyst previews highlight the company’s market opportunity in urology and longer‑term upside scenarios, but these are speculative pending execution and near‑term results. PROCEPT BioRobotics Corporation (PRCT): A Bull Case Theory
• Negative Sentiment: Q4 results missed across the board: EPS of ($0.53) vs. consensus ($0.32) and revenue of $76.38M vs. $93.7M consensus — the primary catalyst for the sell‑off. PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Near‑term outlook weakened materially — Q1 2026 revenue guidance of $79M–$82M is far below the ~$93.7M consensus, indicating a slower start to 2026 and pressuring short‑term revenue visibility. PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
• Negative Sentiment: Analysts responded with downgrades — Bank of America cut to “underperform” with a $20 PT and Oppenheimer trimmed to “market perform,” amplifying selling pressure. Finviz PRCT Quote Page (analyst actions)
• Negative Sentiment: Coverage pieces and market writeups flagged the stock hitting a 52‑week low following the results and guidance update — a technical sign that momentum traders have turned bearish. PROCEPT BioRobotics Stock Hits 52-Week Low – Here’s Why

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Wall Street Zen upgraded PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. UBS Group initiated coverage on PROCEPT BioRobotics in a report on Friday, December 12th. They set a “buy” rating and a $62.00 price target for the company. Jefferies Financial Group raised PROCEPT BioRobotics from a “hold” rating to a “strong-buy” rating in a research report on Friday, December 12th. Piper Sandler restated an “overweight” rating and issued a $50.00 price objective (down from $55.00) on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $55.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $49.90.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd increased its holdings in PROCEPT BioRobotics by 436.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after purchasing an additional 746 shares during the period. JTC Employer Solutions Trustee Ltd acquired a new position in shares of PROCEPT BioRobotics during the third quarter worth about $30,000. Center for Financial Planning Inc. purchased a new stake in shares of PROCEPT BioRobotics during the fourth quarter worth approximately $40,000. Vega Investment Solutions raised its holdings in PROCEPT BioRobotics by 52.0% in the second quarter. Vega Investment Solutions now owns 775 shares of the company’s stock valued at $45,000 after acquiring an additional 265 shares in the last quarter. Finally, US Bancorp DE lifted its stake in PROCEPT BioRobotics by 175.7% in the third quarter. US Bancorp DE now owns 1,693 shares of the company’s stock worth $60,000 after acquiring an additional 1,079 shares during the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics Stock Down 25.3%

The business’s 50 day moving average is $30.37 and its 200-day moving average is $33.71. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20. The company has a market cap of $1.16 billion, a PE ratio of -13.38 and a beta of 0.99.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.